Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Lipid-rich carcinoma of the breast. A clinicopathological study of 49 cases.

Shi P, Wang M, Zhang Q, Sun J.

Tumori. 2008 May-Jun;94(3):342-6.

2.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

3.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
5.

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L.

Ann Oncol. 2008 May;19(5):883-90. doi: 10.1093/annonc/mdm585. Epub 2008 Jan 10.

PMID:
18187484
6.
7.

Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.

Cao L, Sun PL, Yao M, Jia M, Gao H.

Hum Pathol. 2017 Oct;68:166-174. doi: 10.1016/j.humpath.2017.08.032. Epub 2017 Sep 9. Review.

PMID:
28899737
8.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

9.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
10.

Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.

Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, Seidl B, Gibbons K, Pyke C, Shannon C, Woodward N, Armes JE.

J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17.

PMID:
28416639
12.

Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.

Lin Fde M, Pincerato KM, Bacchi CE, Baracat EC, Carvalho FM.

J Clin Pathol. 2012 Jan;65(1):64-8. doi: 10.1136/jclinpath-2011-200318. Epub 2011 Oct 29.

PMID:
22039288
13.

Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.

Cubukcu E, Kanat O, Fatih Olmez O, Kabul S, Canhoroz M, Avci N, Deligonul A, Hartavi M, Cubukcu S, Olmez F, Kurt E, Evrensel T, Gokgoz S, Manavoglu O.

J BUON. 2013 Apr-Jun;18(2):359-65.

PMID:
23818346
14.

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.

Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y, Akiyama F.

Breast Cancer. 2015 Jan;22(1):71-8. doi: 10.1007/s12282-013-0455-5. Epub 2013 Mar 12.

PMID:
23479208
15.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL.

Mod Pathol. 2014 Apr;27(4):554-61. doi: 10.1038/modpathol.2013.153. Epub 2013 Sep 20.

16.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

17.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

18.

Diagnostic utility of snail in metaplastic breast carcinoma.

Nassar A, Sookhan N, Santisteban M, Bryant SC, Boughey JC, Giorgadze T, Degnim A.

Diagn Pathol. 2010 Nov 26;5:76. doi: 10.1186/1746-1596-5-76.

19.

Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.

Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H, Errihani H.

BMC Womens Health. 2012 Oct 7;12:35. doi: 10.1186/1472-6874-12-35.

20.

Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.

Zhao S, Xu L, Liu W, Lv C, Zhang K, Gao H, Wang J, Ma R.

Int J Clin Exp Pathol. 2015 May 1;8(5):5744-8. eCollection 2015.

Supplemental Content

Support Center